PriceTargets.com logo

Mersana Therapeutics - MRSN Stock Price Target and Predictions

  • Consensus Rating: Reduce
  • Consensus Price Target: $8.00
  • Forecasted Upside: 321.05%
  • Number of Analysts: 7
  • Breakdown:
  • 1 Sell Ratings
  • 6 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$1.90 As of 12/1/2023 09:55 PM ET
▲ +0.25 (15.15%)

This chart shows the closing price for MRSN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Mersana Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MRSN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MRSN

Analyst Price Target is $8.00
▲ +321.05% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Mersana Therapeutics in the last 3 months. The average price target is $8.00, with a high forecast of $14.00 and a low forecast of $2.00. The average price target represents a 321.05% upside from the last price of $1.90.

This chart shows the closing price for MRSN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Reduce

The current consensus among 7 investment analysts is to reduce stock in Mersana Therapeutics. This Reduce consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
6/11/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
9/9/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
12/8/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
3/8/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
6/6/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
9/4/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
11/3/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
12/3/2023

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/31/2023WedbushReiterated RatingNeutral$2.00Low
8/8/2023WedbushReiterated RatingNeutral$2.00Low
7/28/2023Robert W. BairdDowngradeOutperform ➝ NeutralLow
7/27/2023JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightLow
7/27/2023CitigroupDowngradeBuy ➝ NeutralLow
7/27/2023BTIG ResearchDowngradeBuy ➝ NeutralLow
7/27/2023GuggenheimDowngradeBuy ➝ NeutralN/A
7/27/2023Truist FinancialReiterated RatingBuy ➝ HoldN/A
7/27/2023WedbushReiterated RatingOutperform ➝ Neutral$12.00 ➝ $2.00N/A
6/16/2023Robert W. BairdLower Target$20.00 ➝ $7.00Low
6/16/2023CitigroupLower Target$15.00 ➝ $10.00Low
6/15/2023JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$11.00 ➝ $5.00Low
6/15/2023BTIG ResearchLower Target$16.00 ➝ $10.00Low
6/14/2023GuggenheimInitiated CoverageBuy$14.00Low
3/16/2023JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$10.00Low
3/1/2023BTIG ResearchLower Target$26.00 ➝ $16.00Low
1/20/2023CitigroupInitiated CoverageBuy$12.00Low
11/21/2022Truist FinancialInitiated CoverageBuy$12.00Low
8/9/2022WedbushReiterated RatingOutperformLow
8/9/2022Robert W. BairdBoost TargetOutperform$18.00 ➝ $20.00Low
8/9/2022SVB LeerinkBoost TargetOutperform$13.00 ➝ $14.00Low
5/10/2022Robert W. BairdLower Target$23.00 ➝ $18.00High
5/9/2022HC WainwrightLower Target$24.00 ➝ $19.00Low
2/18/2022SVB LeerinkLower TargetOutperform$25.00 ➝ $16.00High
11/10/2021Robert W. BairdLower TargetOutperform$30.00 ➝ $23.00Low
9/12/2021BTIG ResearchReiterated RatingBuyHigh
8/30/2021HC WainwrightInitiated CoverageBuy$28.00High
8/12/2021Robert W. BairdReiterated RatingBuy$30.00High
6/29/2021BTIG ResearchReiterated RatingBuy$32.00High
3/30/2021Credit Suisse GroupInitiated CoverageNeutral$18.00High
12/2/2020Stifel NicolausInitiated CoverageBuy$33.00High
11/9/2020SVB LeerinkBoost TargetOutperform$25.00 ➝ $28.00Medium
9/29/2020JPMorgan Chase & Co.Initiated CoverageNeutralMedium
6/24/2020BTIG ResearchBoost TargetBuy$21.00 ➝ $32.00Low
6/23/2020HC WainwrightReiterated RatingBuy$26.00Low
5/28/2020Robert W. BairdBoost TargetOutperform$12.00 ➝ $20.00High
5/27/2020SVB LeerinkBoost TargetOutperform$12.00 ➝ $21.00High
5/27/2020HC WainwrightBoost TargetBuy$13.00 ➝ $26.00High
4/29/2020BTIG ResearchInitiated CoverageBuy$14.00High
3/2/2020HC WainwrightReiterated RatingBuy$13.00High
2/11/2020HC WainwrightReiterated RatingBuy$12.00High
1/21/2020HC WainwrightBoost TargetBuy$7.00 ➝ $12.00High
1/13/2020CowenReiterated RatingBuyHigh
1/10/2020HC WainwrightReiterated RatingBuy$7.00High
11/7/2019HC WainwrightReiterated RatingBuy$7.00Low
6/2/2019CowenReiterated RatingBuyHigh
3/11/2019JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightHigh
3/8/2019Robert W. BairdSet TargetBuy$12.00High
1/4/2019HC WainwrightSet TargetBuy$14.00High
(Data available from 12/4/2018 forward)

News Sentiment Rating

0.47 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2023
  • 3 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
6/7/2023
  • 2 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 7 very negative mentions
Mentions as of
7/7/2023
  • 1 very positive mentions
  • 7 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
8/6/2023
  • 3 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2023
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2023
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/4/2023
  • 4 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2023

Current Sentiment

  • 4 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Mersana Therapeutics logo
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has a research and development collaborations with Janssen Biotech, Inc. and Merck KGaA, as well as collaboration agreement with Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $1.90
Low: $1.47
High: $1.90

50 Day Range

MA: $1.39
Low: $1.11
High: $1.90

52 Week Range

Now: $1.90
Low: $0.80
High: $9.62

Volume

3,085,700 shs

Average Volume

3,384,469 shs

Market Capitalization

$229.10 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.39

Frequently Asked Questions

What sell-side analysts currently cover shares of Mersana Therapeutics?

The following Wall Street research analysts have issued stock ratings on Mersana Therapeutics in the last year: BTIG Research, Citigroup Inc., Guggenheim, JPMorgan Chase & Co., Robert W. Baird, Truist Financial Co., and Wedbush.
View the latest analyst ratings for MRSN.

What is the current price target for Mersana Therapeutics?

6 Wall Street analysts have set twelve-month price targets for Mersana Therapeutics in the last year. Their average twelve-month price target is $8.00, suggesting a possible upside of 321.1%. Guggenheim has the highest price target set, predicting MRSN will reach $14.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $2.00 for Mersana Therapeutics in the next year.
View the latest price targets for MRSN.

What is the current consensus analyst rating for Mersana Therapeutics?

Mersana Therapeutics currently has 1 sell rating and 6 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Reduce."
View the latest ratings for MRSN.

What other companies compete with Mersana Therapeutics?

Other companies that are similar to Mersana Therapeutics include CorMedix, Merrimack Pharmaceuticals, Heron Therapeutics, Ocular Therapeutix and Prelude Therapeutics. Learn More about companies similar to Mersana Therapeutics.

How do I contact Mersana Therapeutics' investor relations team?

Mersana Therapeutics' physical mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company's listed phone number is (617) 498-0020 and its investor relations email address is i[email protected]. The official website for Mersana Therapeutics is www.mersana.com. Learn More about contacing Mersana Therapeutics investor relations.